Apricus Bio To Present at the Rodman & Renshaw 12th Annual Healthcare Conference
Rodman & Renshaw Annual Global Investment Conference NYC-
SAN DIEGO-- (BUSINESS WIRE)-- Apricus Bio, Inc. (Nasdaq: APRI), backed by a revenue generating CRO business and seeking to leverage its proprietary, multi-route NexACT® drug delivery technology and internal pipeline through out-licensing arrangements and partnerships, today announced that Dr. Bassam Damaj, President and Chief Executive Officer, will present at the Rodman & Renshaw 12th Annual Healthcare Conference at 10:25am ET on Tuesday, September 14, 2010, in the Winslow Salon on the 5th floor of the New York Palace Hotel in New York City.
The Company's presentation will be available via webcast and can be accessed at: http://www.wsw.com/webcast/rrshq18/nexm.
About Apricus Bio, Inc.
Backed by a solid, revenue generating CRO business, Apricus Bio has leveraged the flexibility of its proven NexACT® drug delivery technology to enable multi-route administration of new and improved compounds across numerous therapeutic classes. Future growth will be driven primarily through out-licensing of this technology for the development and commercialization of such compounds to pharmaceutical and biotechnology companies, worldwide. Concurrently, the Company is seeking to monetize its existing product pipeline, including compounds from pre-clinical through Phase 3, currently focused on dermatology, sexual dysfunction and cancer. For further information on Apricus Bio and its subsidiaries, visit the following websites: www.apricusbio.com and www.bio-quant.com.
Apricus Bio Contacts:
Apricus Bio Investor Relations:
Paula Schwartz
Apricus Bio, Inc. Rx Communications Group, LLC
(917) 322-2216
[email protected]
Apricus Bio, Inc.
Edward Cox, V.P.
Investor Relations & Corporate Development Apricus Bio, Inc.
(858) 926-5811
[email protected]